Arcutis Biotherapeutics

ARQT · Nasdaq · United States

Share price · ARQT

$27.61+1.07 (+4.03%) 3M

close as of 2026-11-18 · 24h delayed · vol 838K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ARQT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026-5.4%
  2. 5 Nov 2026-20.7%
  3. 19 Oct 2026+10.7%
  4. 15 Oct 2026+10.2%
  5. 9 Oct 2026+8.5%
  6. 16 Sep 2026+11.2%
  7. 7 Aug 2026-4.3%
  8. 7 May 2026-14.5%
  9. 2 Mar 2026-8.2%
  10. 27 Feb 2026-5.6%

Share of unusual movement by asset

For each asset, the share of ARQT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Roflumilast (Zoryve) (Zoryve)
events and moves
95%
Roflumilast (Zoryve foam) (Zoryve foam)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—71%

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
PDE4Small molecule
PsoriasisSeborrheic Dermatitis
Approved
PDE4Small molecule
Atopic DermatitisPsoriasis
Phase 1
CD200RProtein / enzyme therapeutic
Atopic Dermatitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Roflumilast (Zoryve)Phase 3Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Est. primary completion 2028-04-27 · NCT07916480 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

23 February 2027FDA action dateRoflumilast (Zoryve)PDUFA target date 23 Feb 2027 for Zoryve cream 0.05% in infant AD
US, FDA · Source ↗

Recent

8 July 2026Filing acceptedRoflumilast (Zoryve)FDA accepts sNDA for Zoryve cream 0.05% in infant atopic dermatitis
US, FDA · Source ↗
29 June 2026ApprovalRoflumilast (Zoryve)FDA approves ZORYVE cream 0.3% for plaque psoriasis in children as young as 2
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$144M$22M$34M+ $226M short-term inv.—$19M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$130M$20M$34M+ $204M short-term inv.—$13M operating cash flowreport ↗
2026-Q1$105M—$224M$11Mreport ↗
2025-Q3$99M$20M$47M+ $144M short-term inv.—-$1.8M operating cash flowreport ↗
2025-Q2$82M$19M$73M+ $118M short-term inv.$16M$0.3M operating cash flowreport ↗
2025-Q1$64M$18M$54M+ $145M short-term inv.$25M-$30M operating cash flowreport ↗
2024-Q3$45M$20M$135M+ $196M short-term inv.$42M-$35M operating cash flowreport ↗
2024-Q2$31M$19M$85M+ $278M short-term inv.$52M-$45M operating cash flowreport ↗
2024-Q1$22M$23M$191M+ $214M short-term inv.$35M-$32M operating cash flowreport ↗
2023-Q3$38M$26M$108M+ $120M short-term inv.$45M-$44M operating cash flowreport ↗
2023-Q2$4.8M$25M$106M+ $164M short-term inv.$71M-$66M operating cash flowreport ↗
2023-Q1$2.8M$35M$82M+ $251M short-term inv.$80M-$80M operating cash flowreport ↗
2022-Q3$0.7M$70M$83M+ $395M short-term inv.$108M-$68M operating cash flowreport ↗
2022-Q2$0$38M$63M+ $221M short-term inv.$67M-$62M operating cash flowreport ↗
2022-Q1$0$41M$71M+ $274M short-term inv.$64M-$57M operating cash flowreport ↗
2021-Q3$0$41M$53M+ $315M short-term inv.$57M-$41M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$372M$77M$43M+ $178M short-term inv.$4.0M-$5.6M operating cash flowreport ↗

For FY2025, Arcutis reported product revenue of $372.07M, up 123.4% YoY, with R&D spend of $77.05M, up 0.8% YoY. Cash and equivalents were $43.22M, and the company recorded a net loss of $16.14M.

Arcutis raised its full-year 2026 net product revenue guidance to $480M-$495M. Clinical updates included positive topline data from the INTEGUMENT-INFANT Phase 2 trial for ZORYVE cream 0.05% in atopic dermatitis, with an sNDA submission expected in Q2 2026; an accepted sNDA for ZORYVE cream 0.3% in plaque psoriasis with a PDUFA date of June 29, 2026; ongoing Phase 2 studies in vitiligo and hidradenitis suppurativa; and a planned Phase 1 study of ARQ-234. The company also announced expansion of its dermatology sales force, termination of its promotion agreement with Kowa, and positive operating cash flow in Q4 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$167M$76M$72M+ $157M short-term inv.$35M-$112M operating cash flowreport ↗
2023-FY$60M$111M$89M+ $183M short-term inv.$66M-$247M operating cash flowreport ↗
2022-FY$3.7M$182M$55M+ $356M short-term inv.$78M-$258M operating cash flowreport ↗
2021-FY$0$146M$98M+ $291M short-term inv.$52M-$175M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 66 sales ($13.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Welgus Howard G. · directorOption exercise822$6.52$5KForm 4
2026-11-16Welgus Howard G. · directorOption exercise1,018$7.51$8KForm 4
2026-11-16Welgus Howard G. · directorOption exercise2,254$8.63$19KForm 4
2026-11-16Welgus Howard G. · directorOpen-market sale4,728$28.16$133KForm 4
2026-11-16Welgus Howard G. · directorOption exercise (derivative)822——Form 4
2026-11-16Welgus Howard G. · directorOption exercise (derivative)1,018——Form 4
2026-11-16Welgus Howard G. · directorOption exercise (derivative)2,254——Form 4
2026-11-13Watanabe Todd · director, See RemarksGift144,232——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 264 reporting institutions held 132.1M shares ($3.1B, 104.5% of shares outstanding).

#InstitutionSharesValue
1SUVRETTA CAPITAL MANAGEMENT, LLC12,327,000$290.4M
2Frazier Life Sciences Management, L.P.9,874,511$232.6M
3BlackRock, Inc.9,200,411$216.8M
4Rubric Capital Management LP8,271,577$194.9M
5STATE STREET CORP6,296,197$148.3M
6Polar Capital Holdings Plc5,666,940$133.5M
7JENNISON ASSOCIATES LLC4,980,770$117.3M
8VANGUARD CAPITAL MANAGEMENT LLC4,871,536$114.8M
9GILDER GAGNON HOWE & CO LLC4,304,010$101.4M
10MORGAN STANLEY4,218,931$99.4M
11UBS Group AG3,329,224$78.4M
12GEODE CAPITAL MANAGEMENT, LLC3,045,306$71.8M
13D. E. Shaw & Co., Inc.2,496,222$58.8M
14MARSHALL WACE, LLP2,431,778$57.3M
15FRANKLIN RESOURCES INC2,297,943$54.1M